アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Human IL-13 receptor alpha 1 chain extracellular domain cDNA (see relevance text).
Interleukin 13 (IL-13) is a T cell derived cytokine involved in the regulation of inflammatory and immune responses. IL-13 receptor alpha 1 together with IL-4 receptor alpha 1 forms a functional receptor for both IL-4and IL-13, which is why these two cytokines share many of their biological activities. The receptor is found on human B cells, monocytes and endothelial cells. However, no functional receptor is expressed on T cells, which explains why IL-13, in contrast to IL-4, fails to induce TH2-cell differentiation. Antibodies produced from cDNA: Conventional technologies usually either generate antibodies against purified proteins, or against synthetic peptides based on amino acid sequences derived from DNA sequence data. Genetic immunization involves introducing the gene in the form of a cDNA directly into an animal which translates this cDNA into protein thus stimulating an immune response against the foreign protein. Although the synthetic peptide approach is comparable in speed, the quality of antibodies generated by genetic immunization is far superior. This is because the protein is made by the immunized animal, utilzing complex cellular mechanisms that allow it to gain a native conformation. Antibodies are then generated against a native protein, such as is found in the blood or tissues of its host species. Membrane-bound or secreted proteins often create problems for conventional antibody technology because in their native form, they are often modified by glycosylation, or in some cases exist as multiple membrane-spanning proteins that are not soluble following isolation or synthesis in recombinant systems. All of these problems are avoided if the immunized animal makes the protein itself. Antibodies generated by genetic immunization have been shown to have binding affinities to the protein in the sub-nanomolar range, which are approximately 100x higher than conventionally developed antibodies and much higher than single chain antibodies. Results confirm published data for much higher avidity of sera generated by genetic immunization as compared with that gained by immunization with a corresponding recombinant protein.
Our Abpromise guarantee covers the use of ab3772 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.|